Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 02:44PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.64 Insider Own10.60% Shs Outstand64.39M Perf Week-2.44%
Market Cap103.02M Forward P/E- EPS next Y-0.63 Insider Trans0.97% Shs Float57.57M Perf Month19.40%
Income-38.07M PEG- EPS next Q-0.15 Inst Own46.66% Short Float / Ratio1.53% / 7.35 Perf Quarter8.11%
Sales0.00M P/S- EPS this Y31.84% Inst Trans-1.81% Short Interest0.88M Perf Half Y-11.11%
Book/sh0.72 P/B2.21 EPS next Y-3.85% ROA-69.74% Target Price5.50 Perf Year-27.93%
Cash/sh0.77 P/C2.09 EPS next 5Y- ROE-80.42% 52W Range1.11 - 4.16 Perf YTD-47.19%
Dividend- P/FCF- EPS past 5Y4.69% ROI-81.32% 52W High-61.54% Beta2.15
Dividend %- Quick Ratio8.14 Sales past 5Y-36.42% Gross Margin-1282.66% 52W Low44.14% ATR0.11
Employees39 Current Ratio8.14 Sales Q/Q- Oper. Margin0.00% RSI (14)57.47 Volatility10.36% 8.66%
OptionableYes Debt/Eq0.02 EPS Q/Q12.05% Profit Margin- Rel Volume0.30 Prev Close1.57
ShortableYes LT Debt/Eq0.01 EarningsNov 03 BMO Payout- Avg Volume119.62K Price1.60
Recom1.00 SMA208.66% SMA5015.36% SMA2003.50% Volume29,599 Change1.91%
Date Action Analyst Rating Change Price Target Change
Nov-12-21Upgrade Jefferies Hold → Buy $3 → $4
Nov-14-19Initiated ROTH Capital Buy $12
Aug-05-19Downgrade SunTrust Buy → Hold $23 → $5
Aug-05-19Downgrade Piper Jaffray Overweight → Neutral $20 → $6
Aug-05-19Downgrade Jefferies Buy → Hold
Apr-12-19Initiated Piper Jaffray Overweight $20
Dec-18-18Initiated H.C. Wainwright Buy $24
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
Nov-09-23 07:00AM
Nov-05-23 08:51AM
Nov-04-23 01:48AM
Nov-03-23 10:33AM
07:00AM Loading…
Oct-23-23 08:30AM
Oct-20-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:00AM
Aug-17-23 07:00AM
Aug-02-23 07:17AM
Jul-19-23 07:00AM
Jul-13-23 09:29AM
08:00AM Loading…
Jun-26-23 08:00AM
Jun-15-23 08:00AM
Jun-12-23 11:13AM
May-31-23 07:00AM
May-16-23 10:37AM
May-03-23 10:17PM
Apr-26-23 07:00AM
Apr-19-23 10:20AM
Apr-05-23 01:45PM
Mar-31-23 04:30AM
Mar-29-23 07:00AM
Mar-21-23 06:23AM
Mar-20-23 06:35AM
06:47AM Loading…
Mar-17-23 06:47AM
Mar-16-23 07:00AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 07:00AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
Feb-16-23 08:00AM
Feb-15-23 08:00AM
Feb-14-23 06:23AM
Feb-06-23 07:00AM
Jan-22-23 07:30AM
Dec-30-22 07:17AM
Dec-28-22 06:58AM
Dec-26-22 07:14AM
Dec-19-22 09:40AM
Dec-12-22 07:00AM
Dec-02-22 01:18PM
Nov-23-22 09:55AM
Nov-16-22 09:40AM
Nov-12-22 07:14AM
Nov-10-22 09:12AM
Nov-09-22 07:00AM
Nov-08-22 04:05PM
Nov-03-22 09:00AM
Nov-02-22 07:00AM
Oct-10-22 11:57PM
Oct-04-22 12:00PM
Sep-09-22 08:30AM
Sep-07-22 07:00AM
Sep-06-22 07:00AM
Aug-09-22 12:00PM
Aug-03-22 02:00PM
Jul-27-22 04:00PM
Jul-18-22 10:22AM
Jun-03-22 08:36AM
Jun-02-22 04:00PM
Apr-28-22 06:30PM
Apr-25-22 09:00AM
Mar-08-22 04:30PM
Mar-03-22 04:15PM
Mar-02-22 09:15AM
Feb-25-22 09:00AM
Feb-23-22 04:30PM
Dec-13-21 09:00AM
Dec-06-21 09:15AM
Nov-24-21 08:00PM
Nov-23-21 04:30PM
Nov-22-21 04:15PM
Nov-15-21 07:00AM
Nov-11-21 09:00AM
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rock EdwinChief Medical OfficerSep 22Buy1.3830,40341,956375,403Sep 25 04:21 PM
Rock EdwinChief Medical OfficerSep 21Buy1.3835,00048,300345,000Sep 25 04:21 PM
Koenig ScottDirectorJun 01Option Exercise0.6021,00012,60036,750Jun 02 04:10 PM
Hahn Brian M.SVP Finance, CFOMay 17Sale1.953,7007,21553,143May 18 04:27 PM
JUNIUS DANIEL MDirectorMay 10Buy1.5630,00046,80093,250May 11 05:08 PM
Johnson Bruce SSVP & Chief Commercial OfficerMay 08Buy1.5713,50021,195138,980May 09 05:00 PM
Invus Public Equities, L.P.10% OwnerFeb 23Buy1.75200,000350,7608,489,064Feb 23 06:23 PM
Invus Public Equities, L.P.10% OwnerFeb 22Buy1.79150,000268,9958,289,064Feb 23 06:23 PM
Invus Public Equities, L.P.10% OwnerFeb 21Buy1.8550,00092,5008,139,064Feb 23 06:23 PM
Invus Public Equities, L.P.10% OwnerFeb 17Buy1.71200,000341,0008,089,064Feb 17 05:29 PM
Invus Public Equities, L.P.10% OwnerFeb 16Buy1.68315,266531,1297,889,064Feb 17 05:29 PM
Invus Public Equities, L.P.10% OwnerFeb 15Buy2.161,000,0002,155,8007,573,798Feb 17 05:29 PM
Invus Public Equities, L.P.10% OwnerFeb 09Buy3.2411,45137,1236,573,798Feb 13 05:45 PM
Koenig ScottDirectorJan 27Option Exercise2.5510,50026,77515,750Jan 30 04:13 PM
SANDELL SCOTT D10% OwnerJan 26Sale3.123,000,0009,356,4002,237,196Jan 27 05:15 PM
SANDELL SCOTT D10% OwnerJan 25Sale3.26652,0162,128,1153,588,288Jan 27 05:15 PM
SANDELL SCOTT D10% OwnerJan 05Sale2.7671,362196,8593,881,933Jan 06 06:35 PM
SANDELL SCOTT D10% OwnerJan 04Sale2.91101,984296,7433,914,072Jan 04 05:26 PM
SANDELL SCOTT D10% OwnerJan 03Sale2.99174,814522,7113,960,002Jan 04 05:26 PM
SANDELL SCOTT D10% OwnerDec 30Sale3.02121,335366,4324,038,732Jan 04 05:26 PM
Rock EdwinChief Medical OfficerDec 22Buy2.25110,000247,500310,000Dec 27 06:41 PM